[US Stocks] AbbVie, Humira Earnings Growth... Investment Appeal 85 Points "Buy"

ChoiceStockUS, a US stock analysis service, gave AbbVie (ABBV) an investment attractiveness score of 85 and a target price of $123.

AbbVie is a specialty biopharmaceutical company actively involved in immunology and oncology, producing drugs that treat chronic autoimmune diseases, neurological disorders, rheumatism, Parkinson's disease, hepatitis C, and more.

★ Check AbbVie Investment Attractiveness and Target Price

According to ChoiceStockUS, AbbVie ranks 146th out of 5,223 US-listed companies with an investment attractiveness score of 85, placing it in the top 2% of high-quality companies. It received high marks for earnings growth potential and business monopoly power.

★ Check Investment Attractiveness Rankings for All US Stocks

The investment attractiveness score is calculated using a US stock analysis algorithm developed by DataHero, which comprehensively evaluates 22 factors including company growth potential, safety, dividend attractiveness, monopoly power, and cash generation ability. The higher the score, the better the quality of the company.

ChoiceStock's main US stock services include ▲stock recommendations ▲recommended portfolios ▲investment attractiveness scores and target prices for all stocks ▲investment attractiveness rankings for all stocks ▲lists of dividend stocks, growth stocks, and more ▲10-year financial charts and investment indicators ▲dividend information.

★ Apply for a Free Trial of ChoiceStockUS

Recent Hot Issue Stocks

Atec, Kakao, Namsun Aluminum, Atectn, Shinpung Pharmaceutical

※ This content is independent of Asia Economy's editorial direction, and all responsibility lies with the information provider.

This content was produced with the assistance of AI translation services.